Business
Shield Therapeutics (STX) FDA approval opens do...
Shield Therapeutics (STX) FDA approval opens do....
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity05-Aug-2019 / 11:22 GMT/BST\n\nHardman & Co: FDA approval opens door to major US opportunity\n\nShield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru(R)/Accufer(R). News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accufer. Its USP will be that oral Accufer is as effective as intravenous iron. The market capitalisation equates to only 4.4x in-market sales.\n\nPlease click here for the full report:\n\nhttps://www.hardmanandco.com/research/corporate-research/fda-approval-opens-door-to-major-us-opportunity/ \n\n\n To contact us:\n\n Hardman & Co35 New Broad StreetLondonEC2M 1NH\n\n www.hardmanandco.com\n\n Follow us on Twitter @HardmanandCo\n \n \n Contacts:\n\n Dr Martin Hall\n\n Dr Dorothea Hill\n\n Dr Gregoire Pave \n\n +44 20 7194 7622\n \n \n  \n\n [email protected]@[email protected] \n \n Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. \n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high n...